{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:03:48Z","timestamp":1794002628837,"version":"4.8.0"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01299","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T04:21:03Z","timestamp":1528431663000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":349,"title":["Adverse Effects of Immunoglobulin Therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Yi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/biom6010015","article-title":"The production processes and biological effects of intravenous immunoglobulin","volume":"6","author":"Barahona Afonso","year":"2016","journal-title":"Biomolecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.intimp.2017.09.005","article-title":"Immunoglobulin replacement therapy in primary and secondary antibody deficiency: the correct clinical approach","volume":"52","author":"Pecoraro","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/MBC.0b013e3283401490","article-title":"The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials","volume":"21","author":"Qin","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/heartjnl-2012-302126","article-title":"Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis","volume":"99","author":"Chen","year":"2013","journal-title":"Heart"},{"key":"B5","doi-asserted-by":"publisher","first-page":"Cd010369","DOI":"10.1002\/14651858.CD010369.pub2","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","volume":"1","author":"Oaklander","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1212\/WNL.0000000000004365","article-title":"Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial","volume":"89","author":"Beecher","year":"2017","journal-title":"Neurology"},{"key":"B7","first-page":"336","article-title":"Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: a meta-analysis","volume":"30","author":"Olyaeemanesh","year":"2016","journal-title":"Med J Islam Repub Iran"},{"key":"B8","doi-asserted-by":"publisher","first-page":"Cd011367","DOI":"10.1002\/14651858.CD011367.pub2","article-title":"Intravenous immunoglobulin for the treatment of childhood encephalitis","volume":"10","author":"Iro","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1651-2227.2006.tb02222.x","article-title":"Emil Adolf von Behring and serum therapy for diphtheria","volume":"95","author":"Raju","year":"2006","journal-title":"Acta Paediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1172\/JCI101508","article-title":"Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma","volume":"23","author":"Cohn","year":"1944","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.iac.2008.06.004","article-title":"History of immunoglobulin replacement","volume":"28","author":"Eibl","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"B14","first-page":"81","article-title":"High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood","volume":"36","author":"Imbach","year":"1981","journal-title":"Helv Paediatr Acta"},{"key":"B15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00441919","article-title":"Clinical trials of sulfonated immunoglobulin preparation for intravenous administration. II. Adverse reactions","volume":"136","author":"Matsumoto","year":"1981","journal-title":"Eur J Pediatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/00015555-1471","article-title":"Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events","volume":"93","author":"Seidling","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1542\/peds.2007-1218","article-title":"Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content","volume":"121","author":"Manlhiot","year":"2008","journal-title":"Pediatrics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1046\/j.1537-2995.1997.37497265353.x","article-title":"Clinical impact of anti-D in intravenous immunoglobulin","volume":"37","author":"Friedman","year":"1997","journal-title":"Transfusion"},{"key":"B19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1046\/j.1423-0410.2003.00336.x","article-title":"Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity","volume":"85","author":"Thorpe","year":"2003","journal-title":"Vox Sang"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1212\/WNL.59.12_suppl_6.S28","article-title":"Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy","volume":"59","author":"Lemm","year":"2002","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000056085","article-title":"Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases","volume":"62","author":"Sherer","year":"2001","journal-title":"Pharmacology"},{"key":"B22","first-page":"139","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases","volume":"19","author":"Dashti-Khavidaki","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1081-1206(10)61711-5","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency","volume":"92","author":"Aghamohammadi","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaci.2011.01.061","article-title":"Association of anti-IgA antibodies with adverse reactions to gamma-globulin infusion","volume":"128","author":"Rachid","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"Rachid","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","article-title":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions","volume":"23","author":"Bichuetti-Silva","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","article-title":"Adverse effects of intravenous immunoglobulin therapy","volume":"21","author":"Nydegger","year":"1999","journal-title":"Drug Safety"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1046\/j.1537-2995.2003.00519.x","article-title":"Intravenous immune globulins: an update for clinicians","volume":"43","author":"Knezevic-Maramica","year":"2003","journal-title":"Transfusion"},{"key":"B29","first-page":"11","article-title":"Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience","volume":"49","author":"Kaba","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.50.5.1273","article-title":"Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis","volume":"50","author":"Sorensen","year":"1998","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1212\/WNL.59.12_suppl_6.S33","article-title":"Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies","volume":"59","author":"Brannagan","year":"2002","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jaad.2010.12.034","article-title":"Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy","volume":"66","author":"Gerstenblith","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejim.2008.04.022","article-title":"Intravenous immunoglobulins-induced eczematous eruption: a long-term follow-up study","volume":"20","author":"Cohen Aubart","year":"2009","journal-title":"Eur J Intern Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00043426-199705000-00015","article-title":"Cardiac rhythm abnormalities during intravenous immunoglobulin G infusion for treatment of thrombocytopenia","volume":"19","author":"Savasan","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ccr3.329","article-title":"Cardiac rhythm abnormalities during intravenous immunoglobulin G(IVIG) infusion in two newborn infants: coincidence or association?","volume":"3","author":"Tufekci","year":"2015","journal-title":"Clin Case Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MJT.0000000000000654","article-title":"Intravenous immunoglobulin-induced profound bradycardia in a patient with idiopathic thrombocytopenic purpura","author":"Raheja","year":"2017","journal-title":"Am J Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.accpm.2014.08.004","article-title":"A case of circulatory collapse during intravenous immunoglobulin therapy: a manageable adverse effect!","volume":"34","author":"Charhon","year":"2015","journal-title":"Anaesth Crit Care Pain Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1046\/j.1537-2995.2001.41020264.x","article-title":"Transfusion-related acute lung injury after the infusion of IVIG","volume":"41","author":"Rizk","year":"2001","journal-title":"Transfusion"},{"key":"B39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/ajh.21185","article-title":"Transfusion-related acute lung injury following intravenous anti-D administration in an adolescent","volume":"83","author":"Berger-Achituv","year":"2008","journal-title":"Am J Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.090725","article-title":"Images in rheumatology. Transfusion-related acute lung injury during intravenous immunoglobulin treatment","volume":"37","author":"Voulgari","year":"2010","journal-title":"J Rheumatol"},{"key":"B41","first-page":"807","article-title":"Transfusion related acute lung injury with intravenous immunoglobulin","volume":"48","author":"Gupta","year":"2011","journal-title":"Indian Pediatr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1423-0410.2012.01645.x","article-title":"Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient","volume":"104","author":"Stoclin","year":"2013","journal-title":"Vox Sang"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1111\/trf.12731","article-title":"Transfusion-related acute lung injury after transfusion of pooled immune globulin: a case report","volume":"54","author":"Quest","year":"2014","journal-title":"Transfusion"},{"key":"B44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12028-015-0115-z","article-title":"Transfusion-related acute lung injury after IVIG for myasthenic crisis","volume":"23","author":"Reddy","year":"2015","journal-title":"Neurocrit Care"},{"key":"B45","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S0140-6736(12)62197-7","article-title":"Transfusion-related acute lung injury: a clinical review","volume":"382","author":"Vlaar","year":"2013","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s12288-015-0604-4","article-title":"Transfusion related acute lung injury (TRALI): a single institution experience of 15 years","volume":"32","author":"Kumar","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"Daniel","year":"2012","journal-title":"Transfusion"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","article-title":"Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study","volume":"133","author":"Ram\u00edrez","year":"2014","journal-title":"Thromb Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/vox.12025","article-title":"Thromboembolic events associated with immunoglobulin treatment","volume":"105","author":"Funk","year":"2013","journal-title":"Vox Sang"},{"key":"B51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","article-title":"Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study","volume":"308","author":"Rajabally","year":"2011","journal-title":"J Neurol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/imj.12765","article-title":"Extensive cerebral venous sinus thrombosis after romiplostim treatment for immune thrombocytopenia (ITP) despite severe thrombocytopenia","volume":"45","author":"Ho","year":"2015","journal-title":"Intern Med J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.autrev.2015.11.001","article-title":"Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis","volume":"15","author":"Moulis","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1365-2141.2010.08418.x","article-title":"Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study","volume":"152","author":"Severinsen","year":"2011","journal-title":"Br J Haematol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1097\/MPH.0000000000000841","article-title":"Dural venous sinus thrombosis and pulmonary embolism following immunoglobulin treatment in pediatric patient with immune thrombocytopenic purpura","volume":"39","author":"Park","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jpeds.2013.10.025","article-title":"Hospital-associated venous thromboembolism in children: incidence and clinical characteristics","volume":"164","author":"Takemoto","year":"2014","journal-title":"J Pediatr"},{"key":"B57","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1365-2710.2011.01287.x","article-title":"Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure","volume":"37","author":"Bentley","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1253\/circj.69.962","article-title":"Single high-dose intravenous immunoglobulin therapy for Kawasaki disease increases plasma viscosity","volume":"69","author":"Baba","year":"2005","journal-title":"Circ J"},{"key":"B59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/cpt.693","article-title":"Pharmacokinetics and pharmacodynamics of intravenous immunoglobulin G maintenance therapy in chronic immune-mediated neuropathies","volume":"102","author":"Fokkink","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2500\/aap.2016.37.3987","article-title":"Intravenous and subcutaneous immunoglobulin G replacement therapy","volume":"37","author":"Bonilla","year":"2016","journal-title":"Allergy Asthma Proc"},{"key":"B61","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2340\/00015555-0900","article-title":"Not all intravenous immunoglobulin preparations are equally well tolerated","volume":"90","author":"Feldmeyer","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/1060028015576362","article-title":"Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches","volume":"49","author":"Thornby","year":"2015","journal-title":"Ann Pharmacother"},{"key":"B64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1546-0096-9-28","article-title":"Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease","volume":"9","author":"Kemmotsu","year":"2011","journal-title":"Pediatr Rheumatol Online J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/trf.13200","article-title":"Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center","volume":"55","author":"Bharath","year":"2015","journal-title":"Transfusion"},{"key":"B66","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/omcr\/omu051","article-title":"Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain-Barre syndrome","volume":"2014","author":"Jain","year":"2014","journal-title":"Oxf Med Case Rep"},{"key":"B68","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000087720","article-title":"Posterior reversible encephalopathy complicating intravenous immunoglobulins in a patient with Miller-Fisher syndrome","volume":"54","author":"Nakajima","year":"2005","journal-title":"Eur Neurol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.034","article-title":"Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome\/Bickerstaff brain stem encephalitis overlap syndrome","volume":"23","author":"Stetefeld","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1590\/0100-3984.2015.0129","article-title":"Posterior reversible encephalopathy syndrome following immunoglobulin therapy in a patient with Miller-Fisher syndrome","volume":"49","author":"Ribeiro","year":"2016","journal-title":"Radiol Bras"},{"key":"B71","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/ndt\/gfm594","article-title":"Posterior reversible encephalopathy induced by intravenous immunoglobulin","volume":"23","author":"Belmouaz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B72","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1046\/j.1351-5101.2003.00695.x","article-title":"SIADH and seizure associated with immunoglobulin therapy","volume":"10","author":"Kao","year":"2003","journal-title":"Eur J Neurol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1399-3062.2007.00294.x","article-title":"Aseptic meningitis and abducens nerve palsy as a serious side effect of high dose intravenous immunoglobulin used in a patient with renal transplantation","volume":"10","author":"Wright","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.aller.2012.08.003","article-title":"VI nerve palsy after intravenous immunoglobulin in Kawasaki disease","volume":"42","author":"Rodriguez-Lozano","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00296-016-3515-2","article-title":"Abducens nerve palsy in a girl with incomplete Kawasaki disease","volume":"36","author":"Emiroglu","year":"2016","journal-title":"Rheumatol Int"},{"key":"B76","first-page":"60","article-title":"Important drug warning: immune globulin intravenous (human) (IGIV) products","volume":"19","author":"Epstein","year":"2000","journal-title":"Neonatal Netw"},{"key":"B77","volume-title":"Enq\u00eate Officielle Immunoglobulines Humaines: Atteintes R\u00e9nales. Direction de l\u2019Evaluation des M\u00e9dicaments et des Produits Biologiques \u2014 Unit\u00e9 de Pharmacovigilance","year":"2006"},{"key":"B78","first-page":"83","article-title":"Pulmonary and renal toxicity of intravenous immunoglobulin","volume":"36","author":"Rault","year":"1991","journal-title":"Clin Nephrol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0272-6386(96)90505-3","article-title":"Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis","volume":"28","author":"Hansen-Schmidt","year":"1996","journal-title":"Am J Kidney Diseases"},{"key":"B80","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.V8111788","article-title":"Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature","volume":"8","author":"Cayco","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/mus.25693","article-title":"Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders","volume":"56","author":"Levine","year":"2017","journal-title":"Muscle Nerve"},{"key":"B82","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1592\/phco.2005.25.6.886","article-title":"Intravenous immunoglobulin-associated acute renal failure: case series and literature review","volume":"25","author":"Itkin","year":"2005","journal-title":"Pharmacotherapy"},{"key":"B83","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","article-title":"Intravenous immunoglobulin and the kidney \u2013 a two-edged sword","volume":"34","author":"Orbach","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"B84","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/qjmed\/93.11.751","article-title":"Nephrotoxicity of intravenous immunoglobulin","volume":"93","author":"Levy","year":"2000","journal-title":"QJM"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/ndt\/16.7.1513","article-title":"Immunoglobulin as a risk factor for contrast media nephrotoxicity","volume":"16","author":"Bassilios","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"B87","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.anai.2016.11.009","article-title":"Acute renal dysfunction caused by nonsucrose intravenous immunoglobulin in common variable immunodeficiency","volume":"118","author":"Kim","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","article-title":"Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis","volume":"48","author":"Daw","year":"2008","journal-title":"Transfusion"},{"key":"B89","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/tme.12083","article-title":"Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature","volume":"24","author":"Desborough","year":"2014","journal-title":"Transfus Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/cei.12518","article-title":"Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis","volume":"178","author":"Bonilla","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1473-0502(03)00012-0","article-title":"Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome","volume":"28","author":"Chamouni","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/bjh.12182","article-title":"Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy","volume":"160","author":"Mohamed","year":"2013","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1002\/ajh.24931","article-title":"Impact of screening and exclusion of high anti-A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment \u2013 a hospital-based cohort study in the US","volume":"93","author":"Martinez","year":"2017","journal-title":"Am J Hematol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/ene.12287","article-title":"Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders","volume":"21","author":"Markvardsen","year":"2014","journal-title":"Eur J Neurol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1142::AID-MUS8>3.0.CO;2-8","article-title":"Hemolytic anemia associated with intravenous immunoglobulin","volume":"20","author":"Wilson","year":"1997","journal-title":"Muscle Nerve"},{"key":"B96","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.3345\/kjp.2016.59.11.S60","article-title":"A 2-month-old boy with hemolytic anemia and reticulocytopenia following intravenous immunoglobulin therapy for Kawasaki disease: a case report and literature review","volume":"59","author":"Kim","year":"2016","journal-title":"Korean J Pediatr"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1111\/ene.13444","article-title":"Relative leucopenia and hemolytic anemia following infusion of immunoglobulin","volume":"24","author":"Markvardsen","year":"2017","journal-title":"Eur J Neurol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1136\/bmj.296.6631.1262-a","article-title":"Neutropenia caused by intravenous immunoglobulin","volume":"296","author":"Majer","year":"1988","journal-title":"Br Med J"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1136\/bmj.296.6639.1800-a","article-title":"Neutropenia following intravenous immunoglobulin","volume":"296","author":"Veys","year":"1988","journal-title":"Br Med J"},{"key":"B100","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00002826-200311000-00009","article-title":"Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders","volume":"26","author":"Matsuda","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/jnnp.71.4.562","article-title":"Call for guidelines for monitoring renal function and haematological variables during intravenous infusion of immunoglobulin in neurological patients","volume":"71","author":"Bajaj","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B102","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5414\/CNP64246","article-title":"Intravenous immunoglobulin-induced reversible neutropenia in a renal transplant patient","volume":"64","author":"Singh","year":"2005","journal-title":"Clin Nephrol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1399-3038.2009.00885.x","article-title":"Intravenous immunoglobulin-induced neutropenia","volume":"21","author":"Khan","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","article-title":"Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases","volume":"20","author":"Koffman","year":"1997","journal-title":"Muscle Nerve"},{"key":"B105","doi-asserted-by":"publisher","first-page":"c143","DOI":"10.1159\/000104424","article-title":"Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy","volume":"106","author":"Daphnis","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"B106","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jama.272.6.424","article-title":"Outbreak of hepatitis C associated with intravenous immunoglobulin administration \u2013 United States, October 1993-June 1994","volume":"272","year":"1994","journal-title":"JAMA"},{"key":"B107","first-page":"505","article-title":"Outbreak of hepatitis C associated with intravenous immunoglobulin administration \u2013 United States, October 1993-June 1994","volume":"43","year":"1994","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B108","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1006\/clim.2001.5132","article-title":"Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency","volume":"101","author":"Razvi","year":"2001","journal-title":"Clin Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/imj.13314","article-title":"False positive hepatitis B virus core and surface antibodies due to intravenous immunoglobulin","volume":"47","author":"Benwell","year":"2017","journal-title":"Intern Med J"},{"key":"B110","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1471-2334-14-99","article-title":"Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin","volume":"14","author":"Parker","year":"2014","journal-title":"BMC Infect Dis"},{"key":"B111","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/cid\/ciw222","article-title":"Transmission of hepatitis B core antibody and galactomannan enzyme immunoassay positivity via immunoglobulin products: a comprehensive analysis","volume":"63","author":"Ramsay","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B112","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40259-017-0212-y","article-title":"Pathogen safety of a new intravenous immune globulin 10% liquid","volume":"31","author":"Radomski","year":"2017","journal-title":"BioDrugs"},{"key":"B113","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ajoc.2017.03.005","article-title":"Bilateral uveitis following intravenous immunoglobulin administration","volume":"6","author":"Kocak","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B114","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jns.2017.11.002","article-title":"Passively acquired thyroid autoantibodies from intravenous immunoglobulin in autoimmune encephalitis: two case reports","volume":"383","author":"Uchida","year":"2017","journal-title":"J Neurol Sci"},{"key":"B115","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/WNF.0000000000000236","article-title":"Reversible splenial lesion syndrome after intravenous immunoglobulin treatment for Guillain-Barre syndrome","volume":"40","author":"Uygur Kucukseymen","year":"2017","journal-title":"Clin Neuropharmacol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"B117","first-page":"174","article-title":"Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: a controlled trial","volume":"24","author":"Roberton","year":"1988","journal-title":"Aust Paediatr J"},{"key":"B118","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/CND.0b013e3182212589","article-title":"The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders","volume":"12","author":"Souayah","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"B119","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1440-1797.2010.01399.x","article-title":"Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection","volume":"16","author":"Huang","year":"2011","journal-title":"Nephrology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2230.2008.02809.x","article-title":"Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases","volume":"34","author":"Mignogna","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/jca.21416","article-title":"Severe intravenous immunoglobulin-induced hemolysis with pigment nephropathy managed with red cell exchange","volume":"31","author":"Lasica","year":"2016","journal-title":"J Clin Apher"},{"key":"B122","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(95)90346-1","article-title":"Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs","volume":"345","author":"Gardulf","year":"1995","journal-title":"Lancet"},{"key":"B123","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J Clin Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"B126","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South Med J"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"key":"B128","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/2047-783X-15-6-238","article-title":"Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency","volume":"15","author":"Hoffmann","year":"2010","journal-title":"Eur J Med Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10875-010-9417-2","article-title":"Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels","volume":"30","author":"Thepot","year":"2010","journal-title":"J Clin Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"Misbah","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"B131","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s10875-011-9641-4","article-title":"Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam(R), in primary immunodeficiency","volume":"32","author":"Empson","year":"2012","journal-title":"J Clin Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur J Neurol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s10875-013-9985-z","article-title":"Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases","volume":"34","author":"Kanegane","year":"2014","journal-title":"J Clin Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clim.2016.04.001","article-title":"Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia","author":"Spadaro","year":"2016","journal-title":"Clin Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ene.13218","article-title":"Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study","volume":"24","author":"Markvardsen","year":"2017","journal-title":"Eur J Neurol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/mus.25409","article-title":"Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis","volume":"55","author":"Racosta","year":"2017","journal-title":"Muscle Nerve"},{"key":"B138","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"Berger","year":"2011","journal-title":"Clin Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13223-017-0220-y","article-title":"Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders","volume":"13","author":"Ameratunga","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0140-6736(82)92496-5","article-title":"A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus","volume":"1","author":"Barnes","year":"1982","journal-title":"Lancet"},{"key":"B141","doi-asserted-by":"publisher","first-page":"CD001816","DOI":"10.1002\/14651858.CD001816.pub3","article-title":"Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates","volume":"4","author":"Foster","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B142","doi-asserted-by":"publisher","first-page":"Cd003740","DOI":"10.1002\/14651858.CD003740.pub2","article-title":"Oral immunoglobulin for the prevention of rotavirus infection in low birth weight infants","author":"Pammi","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01299\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T07:13:39Z","timestamp":1661411619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01299\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":142,"alternative-id":["10.3389\/fimmu.2018.01299"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01299","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"article-number":"1299"}}